IL216002A - An isolated antibody or antigen-binding fragment from it that binds specifically to 100cd - Google Patents

An isolated antibody or antigen-binding fragment from it that binds specifically to 100cd

Info

Publication number
IL216002A
IL216002A IL216002A IL21600211A IL216002A IL 216002 A IL216002 A IL 216002A IL 216002 A IL216002 A IL 216002A IL 21600211 A IL21600211 A IL 21600211A IL 216002 A IL216002 A IL 216002A
Authority
IL
Israel
Prior art keywords
antigen
binding fragment
specifically binds
isolated antibody
antibody
Prior art date
Application number
IL216002A
Other languages
English (en)
Hebrew (he)
Other versions
IL216002A0 (en
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of IL216002A0 publication Critical patent/IL216002A0/en
Publication of IL216002A publication Critical patent/IL216002A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0001—Archaeal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
IL216002A 2009-05-08 2011-10-27 An isolated antibody or antigen-binding fragment from it that binds specifically to 100cd IL216002A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17682609P 2009-05-08 2009-05-08
US32521310P 2010-04-16 2010-04-16
PCT/US2010/034116 WO2010129917A2 (en) 2009-05-08 2010-05-07 Anti-cd100 antibodies and methods for using the same

Publications (2)

Publication Number Publication Date
IL216002A0 IL216002A0 (en) 2012-01-31
IL216002A true IL216002A (en) 2016-07-31

Family

ID=43050912

Family Applications (3)

Application Number Title Priority Date Filing Date
IL216002A IL216002A (en) 2009-05-08 2011-10-27 An isolated antibody or antigen-binding fragment from it that binds specifically to 100cd
IL244197A IL244197A0 (en) 2009-05-08 2016-02-21 Antibodies against cd100 and methods of using them
IL261348A IL261348A (en) 2009-05-08 2018-08-23 An isolated antibody or part thereof that binds to CD100 for use in the treatment of autoimmune disease, inflammatory disease and/or cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL244197A IL244197A0 (en) 2009-05-08 2016-02-21 Antibodies against cd100 and methods of using them
IL261348A IL261348A (en) 2009-05-08 2018-08-23 An isolated antibody or part thereof that binds to CD100 for use in the treatment of autoimmune disease, inflammatory disease and/or cancer

Country Status (19)

Country Link
US (6) US8496938B2 (enExample)
EP (2) EP3320920A1 (enExample)
JP (3) JP6059013B2 (enExample)
KR (2) KR101754433B1 (enExample)
CN (2) CN102458468B (enExample)
AU (2) AU2010245668B2 (enExample)
CA (1) CA2760890C (enExample)
DK (1) DK2427212T3 (enExample)
EA (1) EA025245B1 (enExample)
ES (1) ES2647823T3 (enExample)
IL (3) IL216002A (enExample)
MX (2) MX353352B (enExample)
NO (1) NO2427212T3 (enExample)
NZ (2) NZ618067A (enExample)
PL (1) PL2427212T3 (enExample)
PT (1) PT2427212T (enExample)
SG (1) SG175417A1 (enExample)
WO (1) WO2010129917A2 (enExample)
ZA (1) ZA201108162B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2427212T3 (enExample) 2009-05-08 2018-01-20
EP2487242A1 (en) * 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
PT2711023T (pt) 2011-05-13 2017-10-02 Univ Nat Corp Tokyo Medical & Dental Promotor da osteogénese
ES2669209T3 (es) * 2011-10-11 2018-05-24 Vaccinex, Inc. Uso de moléculas de unión a semaforina-4D para la modulación de la permeabilidad de la barrera hematoencefálica
US8790652B2 (en) * 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) * 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) * 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
US10626163B2 (en) 2013-01-25 2020-04-21 Brandeis University Methods of modulating GABAergic inhibitory synapse formation and function
ES2687282T3 (es) * 2013-03-18 2018-10-24 Biocerox Products B.V. Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CA3098741A1 (en) * 2013-06-25 2014-12-31 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) * 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
AU2017252427B2 (en) 2016-04-22 2023-07-13 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
MX2019001453A (es) 2016-08-02 2019-06-20 Vaccinex Inc Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas.
US20200055917A1 (en) 2016-09-27 2020-02-20 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
CN110446504B (zh) 2017-03-20 2024-07-26 瓦西尼斯公司 用脑信号蛋白-4d抗体联合表观遗传调节剂治疗癌症
AU2018237300A1 (en) 2017-03-23 2019-10-17 The Trustees Of The University Of Pennsylvania Anti-C5a antibodies and uses thereof
WO2018204895A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
RU2020114641A (ru) 2017-09-26 2021-10-27 Серо Терапьютикс, Инк. Молекулы химерных интернализационных рецепторов и способы применения
EP3774906A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
EP3774864A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
EP3774865A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
CN110713537B (zh) * 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
CN110643635A (zh) * 2018-10-22 2020-01-03 华中科技大学同济医学院附属协和医院 Sema4D/PlexinB1信号通路基因沉默的应用
KR102614472B1 (ko) 2019-03-28 2023-12-14 백시넥스 인코포레이티드 암 요법에 사용하기 위한 세마포린-4d 길항제
CA3142777A1 (en) 2019-06-21 2020-12-24 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
WO2021013061A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 一种人源化抗vegfr2抗体及其应用
US20210032322A1 (en) * 2019-08-01 2021-02-04 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgf-beta and compositions therefor
MX2022016188A (es) 2020-06-25 2023-10-30 Vaccinex Inc Uso de moléculas de unión a semaforina-4d para el tratamiento del síndrome de rett.
CN113583122B (zh) * 2021-07-29 2023-08-29 武汉华美生物工程有限公司 抗人sema4d抗体及其制备方法和应用
CA3231551A1 (en) 2021-09-27 2023-03-30 Maurice Zauderer Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
IL312488A (en) * 2021-11-03 2024-07-01 Mbrace Therapeutics Inc Antibody-drug conjugates against EPHA5 receptor tyrosine kinase
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
CN117866091A (zh) * 2022-10-12 2024-04-12 三优生物医药(上海)有限公司 抗cd100抗体及其用途
CN118108841A (zh) * 2022-11-30 2024-05-31 三优生物医药(上海)有限公司 抗cd100抗体及其用途

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5070192A (en) * 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
DE69128253T2 (de) 1990-10-29 1998-06-18 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
AP257A (en) 1991-04-26 1993-06-03 Surface Active Ltd A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
EP0678523B1 (en) * 1993-01-14 2004-09-15 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-hiv antibody and preparation thereof
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
BRPI9809387B8 (pt) 1997-04-07 2021-05-25 Genentech Inc anticorpo humanizado anti-fator de crescimento endotelial vascular humano e composição que o compreende
AU6897998A (en) 1997-04-11 1998-11-11 Dendreon Corporation Composition and method for inducing an immune response against tumour-rela ted antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
JP4451987B2 (ja) 1998-11-10 2010-04-14 ユニバーシティー オブ ロチェスター 標的抗原に特異的なｔ細胞ならびにこれに基づく方法およびワクチン
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
CN1329060A (zh) * 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人semaphorin蛋白9和编码这种多肽的多核苷酸
CA2429544C (en) 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
ITTO20010128U1 (it) 2001-07-25 2003-01-25 Aris Spa Struttura ausiliaria particolarmente per l'incremento della capacita'di trasporto dei veicoli cingolati polivalenti tipo m 113 e derivati.
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
WO2003101485A1 (en) * 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
KR20160014775A (ko) 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
JP4792392B2 (ja) * 2003-09-11 2011-10-12 コーナーストーン セラピューティクス インコーポレイテッド Ｈｍｇｂ１に対するモノクローナル抗体
WO2005055936A2 (en) 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
BRPI0513666A (pt) 2004-08-05 2008-05-13 Genentech Inc anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
US7919246B2 (en) * 2005-04-07 2011-04-05 Novartis Vaccines And Diagnostics, Inc. SEMA4D in cancer diagnosis, detection and treatment
KR20080073748A (ko) * 2005-11-16 2008-08-11 노파르티스 아게 척수 손상에서의 항-ｎｏｇｏ-ａ 항체 치료를 위한바이오마커
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US7657639B2 (en) * 2006-07-21 2010-02-02 International Business Machines Corporation Method and system for identity provider migration using federated single-sign-on operation
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
DE602008004296D1 (de) * 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
WO2008103392A2 (en) 2007-02-21 2008-08-28 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
US20090181035A1 (en) 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
NO2427212T3 (enExample) 2009-05-08 2018-01-20
US9539320B2 (en) 2009-05-15 2017-01-10 Irx Therapeutics, Inc. Vaccine immunotherapy
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
MX353476B (es) 2010-09-02 2018-01-15 Vaccinex Inc Star Anticuerpos anti-cxcl13 y metodos para usarlos.
PT2711023T (pt) 2011-05-13 2017-10-02 Univ Nat Corp Tokyo Medical & Dental Promotor da osteogénese
KR20140074375A (ko) 2011-10-06 2014-06-17 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 질병 치료에 유용한 항-인간 sema4a 항체
ES2669209T3 (es) 2011-10-11 2018-05-24 Vaccinex, Inc. Uso de moléculas de unión a semaforina-4D para la modulación de la permeabilidad de la barrera hematoencefálica
US8790652B2 (en) * 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
KR102090969B1 (ko) 2012-03-02 2020-03-19 백시넥스 인코포레이티드 Ｂ 세포-매개 염증 질환의 치료 방법
US9375282B2 (en) 2012-03-26 2016-06-28 Covidien Lp Light energy sealing, cutting and sensing surgical device
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
KR102176962B1 (ko) 2013-01-31 2020-11-10 백시넥스 인코포레이티드 면역글로불린 a 수준을 증가시키기 위한 방법
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
CA3098741A1 (en) 2013-06-25 2014-12-31 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
AU2017252427B2 (en) 2016-04-22 2023-07-13 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
MX2019001453A (es) 2016-08-02 2019-06-20 Vaccinex Inc Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas.
BR112019017367A2 (pt) 2017-02-22 2020-04-14 Vaccinex Inc detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias

Also Published As

Publication number Publication date
IL244197A0 (en) 2016-04-21
US20220185884A1 (en) 2022-06-16
KR20120044300A (ko) 2012-05-07
AU2016247068A1 (en) 2016-11-03
US20120270268A1 (en) 2012-10-25
US8496938B2 (en) 2013-07-30
KR20170080705A (ko) 2017-07-10
WO2010129917A3 (en) 2011-01-06
NZ618067A (en) 2015-07-31
CA2760890C (en) 2019-08-20
SG175417A1 (en) 2011-12-29
PT2427212T (pt) 2017-11-20
JP2012525854A (ja) 2012-10-25
AU2010245668A1 (en) 2011-11-24
EP2427212A2 (en) 2012-03-14
NZ596136A (en) 2013-12-20
ES2647823T3 (es) 2017-12-26
IL261348A (en) 2018-10-31
PL2427212T3 (pl) 2018-02-28
US12006364B2 (en) 2024-06-11
EA201171374A1 (ru) 2012-06-29
DK2427212T3 (en) 2017-12-04
EP2427212B1 (en) 2017-08-23
NO2427212T3 (enExample) 2018-01-20
US20100285036A1 (en) 2010-11-11
JP6096946B2 (ja) 2017-03-15
CN108912228B (zh) 2022-03-15
EA025245B1 (ru) 2016-12-30
KR101754433B1 (ko) 2017-07-05
WO2010129917A2 (en) 2010-11-11
US9676840B2 (en) 2017-06-13
CN102458468A (zh) 2012-05-16
MX2011011718A (es) 2012-01-27
US9605055B2 (en) 2017-03-28
IL216002A0 (en) 2012-01-31
US20140072578A1 (en) 2014-03-13
AU2010245668B2 (en) 2016-07-14
US20130274449A1 (en) 2013-10-17
US20170306017A1 (en) 2017-10-26
CA2760890A1 (en) 2010-11-11
JP2016128474A (ja) 2016-07-14
CN108912228A (zh) 2018-11-30
EP3320920A1 (en) 2018-05-16
EP2427212A4 (en) 2012-11-14
MX353352B (es) 2018-01-10
ZA201108162B (en) 2012-07-25
JP2017113017A (ja) 2017-06-29
CN102458468B (zh) 2018-05-18
US11274149B2 (en) 2022-03-15
JP6059013B2 (ja) 2017-01-11
US8816058B2 (en) 2014-08-26

Similar Documents

Publication Publication Date Title
IL216002A (en) An isolated antibody or antigen-binding fragment from it that binds specifically to 100cd
IL205502A (en) A polypeptide binds to an antigen that specifically binds to a1tl
AP3371A (en) Anti-IGF antibodies
IL217919A0 (en) Humanized anti-cdcp1 antibodies
IL220404A (en) Antiseptic antibodies
IL207217A0 (en) Humanized anti-c5ar antibodies
ZA201107529B (en) Humanized axl antibodies
IL218724A0 (en) Endoglin antibodies
ZA201202227B (en) Monoclonal antibodies
EP2331579A4 (en) MONOCLONAL ANTIBODIES
ZA201400768B (en) Interleukin-31 monoclonal antibody
EP2349331A4 (en) HUMANIZED ANTIBODIES TO IL-6
ZA201106480B (en) Humanized anti-cd19 antibody formulations
SG10201601279SA (en) Monoclonal Antibody STRO-4
HUE039677T2 (hu) Humanizált anti-CD28-ellenanyagok
EP2565268A4 (en) NEW MUC1 ANTIBODY
ZA201202793B (en) Humanized antibodies against human il-22ra
EP2463369A4 (en) HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS
PL2463368T3 (pl) Humanizowane przeciwciało anty-oligomer amyloidu B
GB0804686D0 (en) Humanized antibody
GB0804687D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed